U.S. Markets closed

MedMen Reports Fourth Quarter and Fiscal Year 2019 Financial Results - Designated News Release

LOS ANGELES--(BUSINESS WIRE)--

  • Record full year revenue of $130 million, up 227% year over year
  • Fourth quarter revenue of $42 million, up 104% year over year
  • Surpassed $110 million in annualized run-rate retail revenue across California, the largest cannabis market in the world
  • Company is licensed for 70 retail stores and currently operates 32 retail locations across 9 states, including pending acquisitions

 

MedMen Enterprises Inc. (“MedMen” or the “Company”) (MMEN.CN) (MMNFF) today released its consolidated financial results for fourth quarter and fiscal year ended June 29, 2019. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

Management Commentary

“Fiscal 2019 was a transformative year for MedMen, with over two million completed retail transactions to date and revenues increasing 227% year-over-year,” said Adam Bierman, MedMen co-founder and chief executive officer. “Our success was due, largely in part, to our loyal customer base. Throughout the year, we served over one million customers from all 50 states and more than 100 countries. In California, the largest cannabis market in the world, MedMen surpassed a record $110 million in annualized run-rate retail revenue.”

Mr. Bierman continued, “While industry tailwinds propelled us forward over the past twelve months, changing macroeconomic conditions have led us to refocus our strategy, to reevaluate our assets and to determine where it makes most sense to allocate capital going forward. As we progress into the next fiscal year, our go-forward strategy will therefore focus on three key objectives: optimizing our current retail assets, unlocking the further potential of our factories, and leveraging our omnichannel strategy. As we bring all of our factories online and up to full capacity, and simultaneously optimize our current retail assets across our core geographic markets, we continue on our path toward profitability.”

Fourth Quarter Fiscal 2019 Review

Financial:

  • Revenue: Systemwide revenue across MedMen's operations in California, Nevada, New York, Illinois and Arizona increased to $42.0 million for the fourth quarter, up 15% sequentially and 104% year-over-year.
  • Gross Margin: Gross margins across retail operations were 50% in the fourth quarter compared to 53% in the prior quarter. The decline in gross margins was related to new store openings, which initially have lower gross margins.
  • Corporate SG&A: Corporate SG&A totaled $33.0 million in the fourth quarter, a 15% decrease from the fiscal second quarter and 6% decrease from the fiscal third quarter. In total, this represents $22.4 million in annualized savings over two quarters. In May 2019, the Company announced that it would be targeting a 20% overall reduction from the fiscal second quarter.
  • Adjusted EBITDA Loss: The Company reported an Adjusted EBITDA loss of $39.4 million for the fourth quarter, representing an 7% improvement from the previous quarter.

Retail Highlights:

  • California: California retail revenue totaled $27.5 million for the fourth quarter. MedMen increased its total California retail license count to 17. Of these 17 retail licenses, 13 are operational as MedMen stores, including the recently opened MedMen Sorrento Valley location. The Company was also recently awarded a commercial retail license in Pasadena, California. MedMen expects to have a total of 30 operating retail locations in California by the end of calendar year 2020.
  • Nevada: MedMen’s Las Vegas location on Paradise, the closest dispensary to the airport, became the Company’s second best-performing store across the U.S. MedMen’s flagship location in Highland, which is located near the Las Vegas Strip, is currently under construction.
  • Florida: During the quarter, the Company opened its first retail location in the state with the opening of its West Palm Beach store. Florida is the third most populous state with a robust medical cannabis program serving over 200,000 qualified patients.
  • Arizona: The Company continued to operate three retail locations in Arizona, through the acquisitions of Monarch and Level Up, which were both announced in Fiscal 2019. The stores are currently undergoing re-branding and expansion efforts in anticipation of potential regulatory changes in the state that would make Arizona a recreational market.
  • Illinois: Through the acquisition of Seven Point earlier in the year, the Company currently operates a medical dispensary in Oak Park, Illinois.
  • Massachusetts: The Company’s Fenway location is pending final regulatory approval and construction is anticipated to begin in calendar year 2020. In Newton, Massachusetts MedMen has signed a lease on a retail location and now is awaiting pending regulatory approvals.
  • New York: The Company operates four medical dispensaries in the state, with a flagship location on Fifth Avenue near Bryant Park.

Corporate Developments:

  • Southern California: Following the close of a previously announced acquisition, MedMen added a flagship retail location in Long Beach situated strategically between its Santa Ana and LAX stores. The Company also opened a second San Diego retail location in Sorrento Valley. During the quarter, MedMen was also awarded one of six retail licenses available in the City of Pasadena.
  • Northern California: MedMen continued to expand its Northern California retail footprint announcing plans to open a retail store in the city of Vallejo upon completion of a pending acquisition of a retail and distribution license. The Vallejo location will, when opened, be the Company’s fourth retail location in the area, joining existing locations in Emeryville, San Jose and Seaside.
  • Illinois: On June 25, 2019, Illinois Governor J.B. Pritzker signed a landmark bill legalizing adult cannabis use in the state beginning January 1, 2020. This legislation bodes well for MedMen’s Oak Park location as well as assets to be transferred to the Company in Hillcrest, Evanston and the Greater Chicago area. Illinois is projected to be a $2 billion recreational cannabis market at maturity, per Marijuana Business Daily.

Capital Markets and Financing Activities:

  • Credit Facility: In the fourth quarter, MedMen completed amendments to, among other things, eliminate trading price thresholds of the Class B subordinate voting shares necessary under the remaining tranches of the $250 million senior secured credit facility arranged by Gotham Green Partners. The Company is currently in active discussions with Gotham Green Partners to make additional amendments to the convertible debt facility to further align all parties given current market conditions.
  • Equity Investment: Concurrent with the above-mentioned credit facility amendment, Gotham Green Partners, with participation from Wicklow Capital, made an additional $30 million equity investment in the Company.

Fiscal Year 2019 Review

Financial:

  • Revenue: Systemwide revenue for fiscal year 2019 increased to $130 million, up 227% from 2018.
  • Gross Margin: Gross profit for fiscal 2019, before biological asset adjustment, was $56.5 million, as compared to $13.1 million in the previous year. Gross profit margin after biological asset adjustment was 47%, compared to 35% in the previous fiscal year.
  • Adjusted EBITDA: MedMen reported an Adjusted EBITDA loss of $172.0 million for fiscal 2019, compared to an Adjusted EBITDA loss of $50.7 million in the previous year.
  • Net Loss: Net loss was $277.0 million, with net loss attributable to shareholders of MedMen Enterprises $79.1 million or loss of $0.75 per basic and diluted share attributable to MedMen Enterprises shareholders for fiscal 2019, compared to a net loss of $113.9 million, with net loss attribute to shareholders of MedMen Enterprises $68.3 million or loss of $1.69 per basic and diluted share, for fiscal 2018.

Subsequent Events

  • MedMen Delivery: MedMen’s fully owned and operated delivery platform was launched in California and Southern Nevada to provide customers access to quality cannabis and MedMen’s unparalleled retail experience from the comfort of their own homes. MedMen plans to roll out delivery from its Florida retail locations before year end. Total sales through e-commerce have surpassed $5 million in annualized revenue, with over 7,500 delivery transactions to date since the service first launched in August 2019.
  • MedMen Buds: The Company announced its new loyalty program, MedMen Buds, in August 2019. In addition to having exclusive access to sales and discounts, loyalty members earn points for every purchase which can be redeemed for rewards. Currently, MedMen Buds is live in stores across Arizona, California, Florida, and Nevada with over 135,000 members enrolled to date.
  • Continued Florida Expansion: Subsequent to year end, MedMen opened 6 additional Florida locations including in St. Petersburg, Key West, Pensacola, Jacksonville Beach, Central Orlando and Tallahassee. The Company anticipates opening five additional retail locations in the state by the end of 2019 bringing its total Florida store count to 12.
  • M&A: On October 8, 2019, the Company announced the termination of its merger with PharmaCann. The cannabis sector evolved significantly from the initial announcement of the transaction and, with the current macro-environment and future strategic opportunities which exist for the Company, it became clear it was in the best interest of shareholders to terminate the deal. As part of the agreement to terminate, MedMen will forgive $21.0 million owed by PharmaCann under an existing line of credit, and PharmaCann agreed to pay a termination fee to MedMen through a transfer of the membership interest in three entities holding the following four assets: 1) an operational cultivation and production facility in Hillcrest, Illinois, 2) a retail location in Evanston, Illinois, 3) a retail license for Greater Chicago, Illinois, and 4) a license for a vertically integrated facility in Virginia.
  • West Hollywood: The City Council of West Hollywood passed an ordinance to extend the Company’s temporary recreational retail license until January 1, 2021, unless otherwise determined. MedMen continues to work with West Hollywood City Council and various community groups on a long-term resolution.
  • Management: The Company appointed Zeeshan Hyder as Chief Financial Officer, succeeding Michael Kramer on October 7, 2019. Mr. Kramer signed a consulting agreement with MedMen for the remainder of the calendar year.

ADDITIONAL INFORMATION

Additional information relating to the Company’s fourth quarter and fiscal year 2019 results is available on SEDAR at www.sedar.com in the Company’s Annual Financial Statements and Management Discussion & Analysis (“MD&A”) for the quarter.

MedMen refers to certain non-IFRS financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), adjusted EBITDA (defined as earnings before interest, taxes, depreciation, amortization, less certain non-cash equity compensation expense, including one-time transaction fees and all other non-cash items) and four-wall retail gross margins. These measures do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers.

Please see the “Supplemental Information (Unaudited) Regarding Non-IFRS Financial Measures” at the end of the MD&A for more detailed information regarding non-IFRS financial measures.

CONFERENCE CALL AND WEBCAST:

MedMen Enterprises will host a conference call and audio webcast with Chief Executive Officer and Co-Founder Adam Bierman and Chief Financial Officer Zeeshan Hyder today at 5:00 pm Eastern to discuss the financial results in further detail.

Webcast Information:
A live audio webcast of the call will be available on the Events and Presentations section of MedMen’s website at: https://investors.medmen.com/events-and-presentations/default.aspx and will be archived for replay.

Calling Information:
Toll Free Dial-In Number: (844) 559-7829
International Dial-In Number: (647) 689-5387
Conference ID: 3858067

ABOUT MEDMEN:

Founded in 2010, MedMen is North America’s premium cannabis retailer. Founders Adam Bierman and Andrew Modlin have defined the next generation discovery platform for cannabis and all its benefits. A robust selection of high-quality products, including MedMen-owned brands [statemade], LuxLyte and MedMen Red, coupled with a team of cannabis-educated associates cement the Company’s commitment to providing an unparalleled experience. MedMen’s industry-leading technology enables a fully compliant, owned-and-operated delivery service and MedMen Buds, a nationwide loyalty program. MedMen believes that a world where cannabis is legal and regulated is safer, healthier and happier. Learn more at www.medmen.com

Cautionary Note Regarding Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, 15 U.S.C.A. Sections 77z-2 and 78u-5 (Supp. 1996). Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only MedMen’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of MedMen’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but are not limited to, the expected benefits from terminating the merger with PharmaCann, including the ability to complete asset transfers from PharmaCann, expectations regarding the number of locations to be operating in California by the end of calendar year 2020, having 12 stores open in Florida by the end of the calendar year, expected start of construction in Massachusetts in calendar 2020, and expectations for other economic, business, and/or competitive factors, including any indication as to the timing of the Company becoming profitable or achieving any reduction in expenses.

By identifying such information and statements in this manner, MedMen is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedMen to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, MedMen has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: inability to receive the requisite regulatory approvals for the transfers of the entities from PharmaCann, changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws and compliance with extensive government regulation. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although MedMen believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and MedMen does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to MedMen or persons acting on its behalf is expressly qualified in its entirety by this notice.

MEDMEN ENTERPRISES INC.  
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION  
AS OF JUNE 29, 2019 AND JUNE 30, 2018  
(Amounts Expressed in United States Dollars Unless Otherwise Stated)  
   
   

 

 

As Restated -
Note 23

2019

 

 

2018

ASSETS  
   
Current Assets:  
Cash and Cash Equivalents

$ 33,753,751

 

 

$ 79,159,970

 

Restricted Cash

55,618

 

 

6,163,599

 

Accounts Receivable

1,487,430

 

 

318,159

 

Current Portion of Prepaid Rent - Related Party

1,580,205

 

 

1,898,863

 

Prepaid Expenses

14,147,213

 

 

9,387,047

 

Derivative Assets

5,213,126

 

 

-

 

Income Taxes Receivable

3,459,019

 

 

-

 

Biological Assets

3,076,158

 

 

1,952,580

 

Inventory

29,176,192

 

 

6,248,754

 

Other Current Assets

18,913,039

 

 

2,790,772

 

Due from Related Party

4,921,455

 

 

3,509,035

 

   
Total Current Assets

115,783,206

 

 

111,428,779

 

   
Non-Current Assets:  
Prepaid Rent - Related Party, Net of Current Portion

4,327,077

 

 

2,652,149

 

Property and Equipment, Net

220,989,461

 

 

88,748,447

 

Intangible Assets, Net

175,552,837

 

 

48,792,757

 

Goodwill

85,560,531

 

 

30,217,597

 

Other Assets

32,417,123

 

 

12,403,049

 

   
Total Non-Current Assets

518,847,029

 

 

182,813,999

 

   
TOTAL ASSETS

$ 634,630,235

 

 

$ 294,242,778

 

   
LIABILITIES AND SHAREHOLDERS’ EQUITY  
   
LIABILITIES:  
Current Liabilities:  
Accounts Payable and Accrued Liabilities

$ 49,794,041

 

 

$ 17,135,714

 

Income Taxes Payable

16,873,177

 

 

3,305,059

 

Other Current Liabilities

10,550,240

 

 

1,186,148

 

Derivative Liabilities

9,343,485

 

 

-

 

Current Portion of Finance Lease Liability

2,502,813

 

 

-

 

Current Portion of Notes Payable

20,229,641

 

 

52,353,625

 

Due to Related Party

5,640,817

 

 

9,858,445

 

   
Total Current Liabilities

114,934,214

 

 

83,838,991

 

   
Non-Current Liabilities:  
Finance Lease Liability, Net of Current Portion

95,726,766

 

 

-

 

Other Non-Current Liabilities

30,877,794

 

 

-

 

Deferred Tax Liabilities

24,578,609

 

 

11,160,195

 

Senior Secured Convertible Credit Facility

90,270,837

 

 

-

 

Notes Payable, Net of Current Portion

77,392,749

 

 

3,593,334

 

   
Total Non-Current Liabilities

318,846,755

 

 

14,753,529

 

   
TOTAL LIABILITIES

433,780,969

 

 

98,592,520

 

   
SHAREHOLDERS’ EQUITY:  
Share Capital

556,651,469

 

 

129,145,994

 

Additional Paid-In Capital

63,026,656

 

 

47,091,271

 

Accumulated Deficit

(383,622,726

)

 

(67,616,023

)

   
Total Equity Attributable to Shareholders of MedMen Enterprises Inc.

236,055,399

 

 

108,621,242

 

Non-Controlling Interest

(35,206,133

)

 

87,029,016

 

   
TOTAL SHAREHOLDERS’ EQUITY

200,849,266

 

 

195,650,258

 

   
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

$ 634,630,235

 

 

$ 294,242,778

 

   
MEDMEN ENTERPRISES INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE 52 WEEKS ENDED JUNE 29, 2019 AND YEAR ENDED JUNE 30, 2018
(Amounts Expressed in United States Dollars Unless Otherwise Stated)
 
 As Restated -
Note 23 

 13 Weeks Ended 

 

 Three Months Ended 

 

 52 Weeks Ended 

 

 Year Ended 

June 29,

 

 June 30, 

 

June 29,

 

 June 30, 

 2019

 

 

 2018

 

 

 2019

 

 

 2018

 

 
Revenue

 $        41,972,293

 

 $        20,555,442

 

 $      129,963,405

 

 $        39,783,102

 

Cost of Goods Sold

           25,962,076

 

           14,659,409

 

           73,470,844

 

           26,653,267

 

 
Gross Profit Before Fair Value Adjustments

           16,010,217

 

             5,896,033

 

           56,492,561

 

           13,129,835

 

 
Realized Fair Value of Inventory Sold  

           (8,185,745

)

                         -  

 

         (16,037,819

)

                         -  

 

Unrealized Gain on Changes in Fair Value of Biological Assets   

             7,746,190

 

                720,390

 

           20,422,965

 

                720,390

 

 
Gross Profit

           15,570,661

 

             6,616,423

 

           60,877,707

 

           13,850,225

 

 
Expenses:
General and Administrative

           51,326,373

 

           65,521,828

 

         244,047,147

 

           98,180,978

 

Sales and Marketing

             7,427,590

 

             4,730,653

 

           27,548,784

 

             7,014,849

 

Depreciation and Amortization

           10,125,438

 

             2,335,372

 

           20,975,133

 

             5,257,862

 

 
Total Expenses

           68,879,401

 

           72,587,853

 

         292,571,064

 

         110,453,689

 

 
Loss from Operations

         (53,308,740

)

         (65,971,430

)

       (231,693,357

)

         (96,603,464

)

 
Other Expense (Income):
Interest Expense

             4,339,749

 

             3,283,295

 

           12,281,764

 

             5,312,433

 

Interest Income

              (293,832

)

                         -  

 

              (701,789

)

                         -  

 

Amortization of Debt Discount and Loan Origination Fees

             6,764,105

 

           10,802,358

 

           10,535,402

 

           10,802,358

 

Change in Fair Value of Derivatives

           (2,149,747

)

           (2,869,942

)

           (4,451,564

)

           (2,869,942

)

Unrealized Gain on Changes in Fair Value of Investments

           (1,965,000

)

                         -  

 

           (4,259,000

)

                         -  

 

Unrealized Loss on Changes in Fair Value of Contingent Consideration

             8,438,689

 

                         -  

 

             8,438,689

 

                         -  

 

Other Expense

             7,204,633

 

                877,477

 

             9,694,867

 

                877,477

 

 
Total Other Expense

           22,338,597

 

           12,093,188

 

           31,538,369

 

           14,122,326

 

 
Loss Before Provision for Income Taxes

         (75,647,337

)

         (78,064,618

)

       (263,231,726

)

       (110,725,790

)

Provision for Income Taxes

             7,260,133

 

             2,221,848

 

           13,814,885

 

             3,086,081

 

 
Net Loss and Comprehensive Loss

         (82,907,470

)

         (80,286,466

)

       (277,046,611

)

       (113,811,871

)

 
Net Loss and Comprehensive Loss Attributable
    to Non-Controlling Interest

           58,687,386

 

           47,424,931

 

         197,927,087

 

           46,195,848

 

 
Net Loss and Comprehensive Loss Attributable
    to Shareholders of MedMen Enterprises Inc.

 $   (24,220,084

)

 $   (32,861,535

)

 $   (79,119,524

)

 $   (67,616,023

)

 
Loss Per Share - Basic and Diluted:
Attributable to Shareholders of MedMen Enterprises Inc.

 $                (0.15

)

 $                (0.81

)

 $                (0.75

)

 $                (1.67

)

 
Weighted-Average Shares Outstanding -
    Basic and Diluted

      166,307,001

 

        40,480,284

 

      105,915,105

 

        40,480,284

 

MEDMEN ENTERPRISES INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE 52 WEEKS ENDED JUNE 29, 2019 AND YEAR ENDED JUNE 30, 2018
(Amounts Expressed in United States Dollars Unless Otherwise Stated)
 

 

 

As Restated -
Note 23

2019

 

 

2018

 

 
CASH FLOW FROM OPERATING ACTIVITIES:
Net Loss and Comprehensive Loss

$ (277,046,611

)

$ (113,811,871

)

Adjustments to Reconcile Net Loss and Comprehensive Loss to Net Cash Used
in Operating Activities:
Unrealized Gain on Changes in Fair Value of Biological Assets

(20,422,965

)

-

 

Deferred Tax (Recovery) Expense

(5,068,784

)

1,547,027

 

Realized Fair Value of Inventory Sold

16,037,819

 

-

 

Depreciation and Amortization

22,598,860

 

6,030,947

 

Amortization of Debt Discount and Loan Origination Fees

10,535,402

 

10,802,358

 

Loss on Sale of Property

1,135,495

 

-

 

Accretion of Deferred Gain on Sale of Property

(528,290

)

-

 

Unrealized Gain on Changes in Fair Value of Investments

(4,259,000

)

-

 

Loss on Extinguishment of Debt

1,164,054

 

-

 

Share-Based Compensation

32,721,458

 

31,360,669

 

Write-off of Intangible Assets

-

 

19,003

 

Issuance to Shareholders of Ladera - Common Shares and Subscription Receipts

-

 

4,899,215

 

Shares Issued for Acquisition Costs

1,112,820

 

-

 

Change in Fair Value of Derivatives

(4,451,564

)

(2,869,942

)

Changes in Operating Assets and Liabilities:
Accounts Receivable

(1,169,271

)

(318,159

)

Notes Receivable

-

 

-

 

Prepaid Rent - Related Party

(1,356,270

)

2,025,000

 

Prepaid Expenses

(4,760,166

)

(7,326,261

)

Income Taxes Receivable

(3,459,019

)

-

 

Other Current Assets

3,261,568

 

(720,390

)

Biological Assets

(19,132,047

)

(7,249,667

)

Inventory

995,821

 

-

 

Due from Related Party

(1,412,420

)

456,102

 

Other Assets

(20,010,746

)

(11,226,093

)

Accounts Payable and Accrued Liabilities

31,618,214

 

15,685,561

 

Income Taxes Payable

12,920,318

 

-

 

Other Current Liabilities

(10,603,378

)

(789,193

)

Due to Related Party

(4,217,628

)

2,609,179

 

Other Non-Current Liabilities

7,696,467

 

-

 

 
NET CASH USED IN OPERATING ACTIVITIES

(236,099,863

)

(68,876,515

)

-

 

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of Property and Equipment

(124,968,929

)

(59,589,669

)

Capitalization of Internally Developed Software

(3,084,097

)

-

 

Purchase of Investments

(8,759,791

)

-

 

Proceeds from Sale of Property

96,373,319

 

-

 

Cash Payments for Asset Acquisitions

(19,780,494

)

-

 

Purchase of Management Agreement

-

 

(3,999,999

)

Acquisition of Businesses, Net of Cash Acquired

(26,661,541

)

(28,425,000

)

Restricted Cash

6,107,981

 

(3,973,532

)

-

 

NET CASH USED IN INVESTING ACTIVITIES

(80,773,552

)

(95,988,200

)

-

 

CASH FLOWS FROM FINANCING ACTIVITIES:
Private Placement in Connection with Reverse Take-Over

-

 

101,802,288

 

Issuance of MM CAN USA, Inc. Class B Shares for
Exercise of MedMen Corp Warrants

-

 

1,289,010

 

Non-Brokered Private Placement

-

 

36,011,152

 

Issuance of Subordinate Voting Shares for Cash

128,595,775

 

-

 

Exercise of Warrants for MedMen Corp Redeemable Shares

8,521,268

 

-

 

Contributions from Members

-

 

21,904,035

 

MM Enterprises USA, LLC Formation and Rollup

-

 

5,206,023

 

Proceeds from Issuance of Senior Secured Convertible Credit Facility

100,000,000

 

-

 

Proceeds from Issuance of Notes Payable

93,943,539

 

75,283,358

 

Principal Repayments of Notes Payable

(54,472,654

)

(23,363,562

)

Principal Repayments of Finance Lease Liability

(1,114,503

)

-

 

Debt Issuance Costs

(4,296,229

)

-

 

Cash Received from Issuance of Class D Units

-

 

9,850,000

 

Contributions - Non-Controlling Interest

290,000

 

10,322,355

 

-

 

NET CASH PROVIDED BY FINANCING ACTIVITIES

271,467,196

 

238,304,659

 

-

 

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

(45,406,219

)

73,439,944

 

Cash and Cash Equivalents, Beginning of Period

79,159,970

 

5,720,026

 

-

 

CASH AND CASH EQUIVALENTS, END OF PERIOD

$ 33,753,751

 

$ 79,159,970

 

-

 

-

 

 
CASH PAID DURING PERIOD FOR:
Interest

$ 13,372,175

 

$ 5,163,199

 

 
MEDMEN ENTERPRISES INC.
NON-IFRS RECONCILIATION
FOR THE 13 AND 52 WEEKS ENDED JUNE 29, 2019 AND THREE MONTHS AND YEAR ENDED JUNE 30, 2018
(Amounts Expressed in United States Dollars Unless Otherwise Stated)
 
 

 

 

 

 

 

 

As Restated -
Note 23

13 Weeks Ended

 

Three Months Ended

 

52 Weeks Ended

 

Year Ended

June 29,

 

June 30,

 

June 29,

 

June 30,

2019

 

 

2018

 

 

2019

 

 

2018

 

 
Net Loss (IFRS)

$ (82,907,471

)

$ (80,286,466

)

$ (277,046,611

)

$ (113,811,871

)

 
Add (Deduct) Impact of:
Transaction Costs

6,848,941

 

5,099,137

 

17,036,191

 

9,203,143

 

Share-Based Compensation

3,421,371

 

30,820,753

 

32,123,699

 

31,360,669

 

Other Non-Cash Operating Costs

4,329,137

 

(2,700,332

)

(2,601,148

)

(2,700,332

)

 
Total Adjustments

14,599,449

 

33,219,558

 

46,558,742

 

37,863,480

 

 
Adjusted Net Loss (Non-IFRS)

$ (68,308,022

)

$ (47,066,908

)

$ (230,487,869

)

$ (75,948,391

)

 
Net Loss (IFRS)

$ (82,907,471

)

$ (80,286,466

)

$ (277,046,611

)

$ (113,811,871

)

 
Add (Deduct) Impact of:
Net Interest and Other Financing Costs

5,186,041

 

3,283,296

 

11,579,975

 

5,312,434

 

Provision for Income Taxes

7,260,133

 

2,348,810

 

13,814,885

 

3,213,043

 

Amortization and Depreciation

16,433,671

 

13,339,503

 

33,129,440

 

16,833,303

 

 
Total Adjustments

28,879,845

 

18,971,609

 

58,524,300

 

25,358,780

 

 
EBITDA (Non-IFRS)

$ (54,027,626

)

$ (61,314,857

)

$ (218,522,311

)

$ (88,453,091

)

 
EBITDA (Non-IFRS)

$ (54,027,626

)

$ (61,314,857

)

$ (218,522,311

)

$ (88,453,091

)

 
Add (Deduct) Impact of:
Transaction Costs

6,848,941

 

5,099,137

 

17,036,191

 

9,203,143

 

Share-Based Compensation

3,421,371

 

30,820,753

 

32,123,699

 

31,360,669

 

Other Non-Cash Operating Costs

4,329,137

 

(2,700,332

)

(2,601,148

)

(2,700,332

)

 
Total Adjustments

14,599,449

 

33,219,558

 

46,558,742

 

37,863,480

 

 
Adjusted EBITDA (Non-IFRS)

$ (39,428,177

)

$ (28,095,299

)

$ (171,963,569

)

$ (50,589,611

)

SOURCE: MedMen Enterprises

View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005715/en/